- Trial phase
- Phase 3
- Time to market
- If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
- Why 7/10
- The next hard, dated catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027 (roughly 7 months from now). Cadisegliatin is vTv's lead and essentially only late-stage asset, making this a make-or-break binary event for a company with a ~$83M market cap. However, the readout is still ~7 months away, and vTv has a small pipeline beyond cadisegliatin (other early-stage programs), so it is not a pure single-asset binary at the 9-10 level. Score of 7 reflects a high-impact pivotal readout within ~6-12 months on the company's dominant asset.
The next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.
Price Chart
Executive Summary
Cadisegliatin (TTP399) is vTv Therapeutics' lead asset, an oral, liver-selective glucokinase activator being developed as a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D). The Phase 3 CATT1 trial completed enrollment with 166 patients in October 2026, with topline results expected mid 2027. The drug has FDA Breakthrough Therapy designation (May 2026) and Orphan Drug Designation (October 2026). Phase 2 SimpliciT-1 data showed HbA1c improvement and fewer severe hypoglycemia events. vTv is a single-asset, late-stage biotech with a market cap around $83 million and a mean analyst price target of $56 (166% upside from $21.03), but the stock trades near its 52-week low, reflecting execution risk and the long wait for the pivotal readout.
How It Works
Cadisegliatin is a pill that activates an enzyme called glucokinase specifically in the liver. This enzyme acts as a glucose sensor, helping the liver better regulate blood sugar levels. Because it works only in the liver (liver-selective), it is designed to lower blood sugar without causing dangerously low blood sugar (hypoglycemia), a major risk with insulin therapy. It is being studied as an add-on (adjunctive) therapy to insulin for people with type 1 diabetes, meaning they would still take insulin but could potentially need less of it and have fewer dangerous lows.
Trial Status
The pivotal Phase 3 CATT1 study completed enrollment in October 2026 with 166 participants randomized. Topline results are expected around mid 2027. A separate Phase 2a pilot study (Hybrid CATT1) evaluating cadisegliatin in patients using hybrid closed-loop insulin pumps began enrolling in October 2026. The Phase 2 SimpliciT-1 study (published in Diabetes Care, 2021) showed HbA1c improvement and fewer severe hypoglycemia events with a favorable safety profile.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 CATT1 topline results expected mid 2027
- Phase 2a Hybrid CATT1 pilot study interim data (timing not specified)
- Potential partnership or licensing deal for cadisegliatin
- FDA regulatory milestones given Breakthrough Therapy designation
Source Filing
The SecBot filing or press-release report that triggered this drug report:
vTv Therapeutics Inc. PRESS-RELEASE VTVT ·Originating report